Home CONTACT Neoplasma 2009 Neoplasma Vol.56, No.2, p.101-107, 2009

Journal info

6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal

Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.56, No.2, p.101-107, 2009

Title: Frequency of the three most common polymorphisms in the MDR1 gene in Slovak population
Author: T. Krivulcik, J. Sedlak, Z. Bartosova

Abstract: The human multidrug resistance gene (MDR1) is encoding the transmembrane transporter P-glycoprotein (P-gp) which plays an important role in the efflux of various drugs and thus is potentially influencing the drug-treatment outcome. It has been indicated that the level of P-gp activity may be affected by the presence of single nucleotide polymorphisms (SNP) in the gene which led to the studies estimating MDR1-SNP frequencies in various populations. Here, we have investigated the occurrence of seven SNP in the MDR1 gene for the first time in Slovak population using multiplex SNaPshot genotyping method. The allelic frequencies of the most common gene variants, i.e. 1236C>T, 2677G>T, 2677G>A and 3435C>T were estimated to be 42.5%, 43.5%, 2%, and 44.5%, respectively. We found that the most prevalent haplotype in Slovak population is 1236C-2677G-3435C occurring in 42.2% of individuals. Our preliminary data show that it is reasonable and feasible to utilize MDR1 genotypes and haplotypes in Slovak patients, e.g. those with acute myeloid leukemia, in order to adjust the individual effective drug dosage and predict the patient’s response to the treatment as well as the treatment outcome.

Keywords: MDR1 gene, P-glycoprotein, polymorphisms, MDR1 haplotypes, Slovak population
Year: 2009, Volume: 56, Issue: 2 Page From: 101, Page To: 107
Price: 16.80 €

© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.